Video

Urology Times 50 Innovations Series: BCG therapy for bladder cancer

"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.

As part of the Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the many ways in which BCG has improved the management of patients with bladder cancer. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
DNA helix | Image Credit: © Radomir Jovanovic - stock.adobe.com
Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Related Content
© 2025 MJH Life Sciences

All rights reserved.